VBI Vaccines Inc. is hoping that the price point for its new hepatitis B vaccine, Sci-B-Vac, as well as a favorable outcome against GlaxoSmithKline PLC’s Engerix-B, will give the trivalent vaccine a leg up in the market. Sci-B-Vac showed non-inferiority overall, and superiority in key subgroups, in its first Phase III trial.
VBI Looking To Market More Potent, Less Expensive Hepatitis B Vaccine
Sci-B-Vac was shown more effective at fewer doses than Engerix-B in a Phase III study. VBI Vaccines sees its hepatitis B vaccine hitting potential markets by 2021.
More from Anti-infective
• By
The US FDA approved Blujepa for the treatment of uncomplicated urinary tract infections, marking the first new mechanism of action for the infection in more than 30 years.
• By
Professor Anil Koul shares vignettes of his life and career trajectory, a captivating mix of hope, science and destiny that took him to the lab of eminent cancer biologist Alex Ullrich at the Max Planck Institute and also saw him contribute to the development of breakthrough TB drug bedaquiline. He also talks about Medicine 3.0 and the intersection of science and spirituality.
• By
The company is developing doravirine and islatravir together as an alternative to therapies containing integrase inhibitors, like Biktarvy, especially as HIV patients age.
• By
The two companies were among those presenting data at CROI that highlighted the next frontiers of competition in the HIV space.
More from Therapy Areas
• By
The company plans a tiered sales approach as it targets endocrinologists for hypothalamic obesity, which is more widely diagnosed than its current indication for Bardet-Biedl syndrome.
• By
The pact could be worth more than $2.6bn and adds to growing big pharma investment in the technology.
• By
Following the near-total dominance of IgG antibodies, the UK group is backing the potential of IgA and IgE-based therapies to transform cancer treatment with the purchase of US-headquartered TigaTx.